Growth Hormone Secretagogues Guide

Growth hormone secretagogues do not replace growth hormone directly. They ask the pituitary to release its own GH pulse. That distinction matters because the goal is not simply "more GH." The useful question is what job the GH axis is being asked to do: visceral fat reduction, sleep-window recovery, lean-mass support during a GLP-1 cut, appetite/weight gain, or clinician-managed replacement.

For peptide users, the practical center of gravity is narrower than the old comparison tables suggest. Ipamorelin is usually the modern GHRP-style default because it gives the ghrelin-receptor GH pulse with less endocrine noise than GHRP-2 or GHRP-6. Tesamorelin is the visceral-fat and recomp workhorse. Sermorelin is the gentler GHRH-side option. CJC-1295 no-DAC remains popular in CJC/ipamorelin blends, but its evidence base is much thinner than its market presence.

The evidence leaderboard is still useful. It just should not be the first decision. A compound can have strong trials for a narrow medical setting and still be the wrong everyday peptide-user choice; another can have weak direct trial data but fit the practical architecture better.

At a Glance

Clean bedtime GH pulse

Ipamorelin

Short GH pulse with lower hunger, cortisol, ACTH, and prolactin pressure than older GHRPs

Deep abdominal fat / visceral-fat phenotype

Tesamorelin

Strongest clinical signal for visceral-fat reduction and useful in recomp / GLP-1 lean-mass support

Gentler GHRH-side nudge

Sermorelin

Short GHRH fragment with prior FDA history and conservative pulse logic

Popular GH stack

CJC-1295 no-DAC + Ipamorelin

GHRH-side plus ghrelin-side pulse architecture

Oral GH / appetite / weight gain

MK-677

Raises GH and IGF-1 without injections

Legacy high-GH stimulation

GHRP-2 / GHRP-6

Older GH-releasing peptides with human endocrine data

Fasted-window dependent; chronic SubQ body-composition use is not trial-proven

IGF-1, glucose, edema, carpal-tunnel-like symptoms

Depends on pituitary reserve; adult outcomes are thin

Exact pair has zero direct human trials

Hunger, edema, glucose drift, and heart-failure signal in frail users

More appetite, flushing, cortisol/prolactin spillover, histamine reactions

The Decision Map

If the goal is visceral fat or GLP-1 lean-mass support

Tesamorelin is the most body-composition-specific GHRH analog in this class, with Phase III trial evidence for deep abdominal fat reduction. The peptide-user translation is not "generic weight loss." It is abdominal-fat, waist, liver-fat, or GLP-1 lean-mass support, set against a base of protein and resistance training.

Typical peptide-user dosing is 1-2 mg SubQ once daily, usually in the evening. The protocol is daily; once-weekly tesamorelin is not the studied cadence. The monitored markers are IGF-1, glucose, edema, joint aching, and carpal-tunnel-like symptoms.

If the goal is sleep-window recovery or a lower-noise GH pulse

Ipamorelin is usually the modern default. It asks the pituitary for a short GH pulse through the ghrelin receptor, but it brings less of the signal users usually dislike from older GHRPs: hunger, cortisol, ACTH, and prolactin.

Typical peptide-user dosing is 100-300 mcg SubQ at bedtime, with optional 1-3x/day pulse stacking in more advanced protocols. The bedtime pulse is a fasted one: at least 2 hours after food and about 60-90 minutes before sleep. A late meal or insulin-heavy snack works against the pulse the protocol is built around.

If the goal is a conservative GHRH-side option

Sermorelin is the gentler GHRH-side option. It is shorter acting than tesamorelin and more dependent on pituitary reserve, but that can be an advantage for users who want a softer nudge or a more legally defensible compounding history.

Typical peptide-user dosing is 200-500 mcg SubQ, with bedtime as the standard pulse. Some adult community protocols split this 1-3x/day, but the bedtime dose is the baseline because it matches the natural overnight GH window. It pairs logically with ipamorelin when the goal is synchronized GHRH plus ghrelin-receptor signaling.

If the goal is the common "CJC/Ipa" stack

The architecture is sound: one GHRH-receptor compound plus one ghrelin-receptor compound, dosed in the same pulse window. That is why CJC-1295 no-DAC + ipamorelin became so popular.

The evidence caveat is also real. CJC-1295 no-DAC, also called Modified GRF (1-29), has zero published human trials. Human data labeled "CJC-1295" used the DAC version, which is a different long-acting compound. The CJC/Ipa stack is mechanism-compatible and widely used, but not directly proven.

If the user wants oral GH support

MK-677 is the oral outlier. It is not a peptide; it is a small-molecule ghrelin-receptor agonist. It can raise GH and IGF-1 for months and increase fat-free mass, but the best older-adult trial did not translate that mass into strength or function. Appetite, edema, glucose drift, and cardiovascular caution are the trade.

Typical dosing is 10-25 mg orally daily. It is a poor fit for glucose-vulnerable users, edema-prone users, heart-failure risk, or anyone trying to cut appetite on a GLP-1.

If the user asks about GHRP-2 or GHRP-6

For most users ipamorelin covers this ground unless the older profile is specifically wanted. GHRP-2 and GHRP-6 are useful historical and mechanistic comparators, but they are noisier: more appetite, more flushing, more cortisol/prolactin spillover, and more local histamine-style reactions.

GHRP-6 is the appetite-heavy legacy option. GHRP-2 is the lower-noise of the two older GHRPs and serves as the historical synergy anchor, but for modern body-composition or sleep-window recovery use, ipamorelin usually carries the same practical intent with fewer liabilities.

Compound Profiles

Tesamorelin

Tesamorelin is the evidence leader for visceral fat. The strongest trial signal is deep abdominal-fat reduction, not general scale-weight loss. That makes it especially relevant for users with a waist / visceral-fat phenotype, fatty-liver context, or GLP-1-driven weight loss where lean-mass preservation and tissue quality matter.

The limitation is monitoring. Tesamorelin is still a GH-axis drug. The monitored markers are IGF-1, fasting glucose or HbA1c, edema, joint aching, carpal-tunnel-like symptoms, and malignancy-risk context. Benefit can fade after discontinuation, so the practical question is whether the user has a real substrate for the compound to work on.

Ipamorelin

Ipamorelin’s appeal is selectivity. It releases GH without the same appetite, cortisol, ACTH, and prolactin load that made older GHRPs messy. That is why it became the default ghrelin-receptor partner for CJC no-DAC or sermorelin.

The limitation is evidence. The human efficacy program used short-course IV dosing for postoperative ileus and failed its endpoint. Chronic SubQ body-composition use is a peptide-user translation from mechanism, acute pharmacology, and field practice. That does not make it useless; it means the claim should stay scoped.

Sermorelin

Sermorelin asks the pituitary for a GHRH-side pulse. It is less forceful than tesamorelin and usually less commercially glamorous than CJC/ipamorelin blends, but it has a real regulatory history and a conservative logic. It works best when the pituitary still has reserve.

Adult body-composition claims need one extra caveat: the older-adult study often cited for sermorelin used a close GHRH analog, not strict sermorelin itself. That does not erase the signal, but it does keep adult anti-aging claims in the "modest and extrapolated" lane.

The main mistake is expecting sermorelin to override a damaged axis. Secretagogues require functioning somatotroph reserve. If the pituitary cannot respond, the answer may be clinical GH evaluation rather than more peptide.

CJC-1295 No-DAC

CJC-1295 no-DAC is the grey-market name usually used for Modified GRF (1-29). It is short acting and designed for daily or multi-daily pulse timing. It is usually paired with ipamorelin.

The naming problem matters. CJC-1295 with DAC has human trials and a week-long half-life. CJC no-DAC has no human trials and a short pulse cadence. They are not interchangeable protocols.

CJC-1295 DAC

CJC-1295 DAC is the long-acting albumin-binding version. It can sustain GH and IGF-1 elevation for days after one injection while preserving pulsatility in the published trial data. Weekly convenience is the appeal.

The downside is tonic exposure and cardiovascular caution. The historical Phase II program stopped after a post-dose myocardial infarction death attributed to pre-existing coronary disease, not clearly the drug, but the class-level lesson remains: cardiovascular substrate matters.

MK-677

MK-677 is convenient because it is oral. That convenience also makes it easy to underestimate. It acts through the ghrelin receptor for a long time, so appetite and fluid retention are part of the practical identity. It can raise IGF-1 and fat-free mass, but users should not assume that automatically means strength, better function, or cleaner body composition.

It is best reserved for users who understand the trade: appetite and weight gain may be features in an underweight or post-illness case, but liabilities in a recomp, GLP-1, prediabetic, or edema-prone case.

GHRP-2 and GHRP-6

GHRP-2 and GHRP-6 helped define the class. They still explain why GHRH plus ghrelin-receptor stimulation works. They are not the modern first pick for most users.

GHRP-2 is the more useful older comparator. GHRP-6 is the appetite-forward option. Both can bring more flushing, hunger, cortisol, prolactin, and water retention than ipamorelin.

How GH Secretagogue Stacks Work

The stack logic is one GHRH-side signal plus one ghrelin-receptor signal. Pairing two compounds from the same side is not synergy; it is dose splitting.

Sermorelin + Ipamorelin

Conservative modern pairing: GHRH-side pulse plus lower-noise ghrelin-side pulse

CJC no-DAC + Ipamorelin

Popular commercial pairing; mechanism-compatible, no direct human trial

Tesamorelin + Ipamorelin

Advanced body-composition pairing; human data support tesamorelin alone, not the stack

CJC DAC + Ipamorelin

Cadence-mismatched: weekly GHRH-side exposure plus daily ghrelin-side pulse

Ipamorelin + GHRP-2

Same receptor side; not a true synergy architecture

Sermorelin + Tesamorelin

Same receptor side; choose one GHRH analog instead

Timing matters. The bedtime pulse runs low-insulin: at least 2 hours after food, ideally 60-90 minutes before sleep. Extra morning or afternoon pulses track the same window rather than landing on a post-meal insulin spike. Training and protein decide whether the GH / IGF-1 signal turns into recovery and lean-mass support or just water, hunger, and soft scale weight.

Histamine, Flushing, and Injection-Site Reactions

GH peptides can cause a small itchy bump, warmth, flushing, or a local welt. This is often a local mast-cell reaction to peptide chemistry and concentration rather than a true allergy. Positively charged peptides can activate skin mast cells directly, especially if injected too shallowly or at high local concentration.

Relative pattern:

GHRP-6

Highest practical risk; appetite-heavy and flush-prominent

GHRP-2

Moderate; usually less than GHRP-6 but noisier than ipamorelin

Low to moderate; more selective but not reaction-proof

Moderate; longer peptide sequence and injection-site reactions matter

Technique changes often help: true SubQ depth rather than shallow intradermal placement, slower injection, lower concentration, site rotation, and avoiding irritating diluent when reactions repeat. Benzyl alcohol can irritate some users; BAC water with sodium chloride is an option when sermorelin or ipamorelin welts keep recurring, but it is not automatically required. Persistent hives away from the injection site, facial swelling, throat tightness, wheezing, or worsening systemic reactions are a different category — a systemic allergic signal that marks a stop-and-evaluate point rather than a technique tweak.

Safety and Monitoring

GH secretagogues preserve more feedback than exogenous HGH, but they still load the GH / IGF-1 risk surface. The monitoring burden rises when the user has prediabetes, type 2 diabetes, edema, untreated sleep apnea, hypertension, cardiovascular disease, or high baseline IGF-1.

Practical monitoring:

IGF-1

Confirms whether the GH-axis signal is rising too far

Fasting glucose / HbA1c

GH and ghrelin-receptor activation can worsen glucose handling

Edema, numbness, carpal-tunnel-like symptoms

Common signs of too much GH / IGF-1 effect

Blood pressure

Fluid retention and GH-axis activation can stress vulnerable users

Sleep apnea symptoms

GH-axis water retention can worsen airway issues

Hard cautions include active malignancy, pregnancy, uncontrolled diabetes, uncontrolled cardiovascular disease, heart failure history, significant edema, and disrupted hypothalamic-pituitary anatomy. If the axis is damaged, secretagogues may fail where clinician-managed replacement would be the real medical pathway.

Regulatory Context

Regulatory status should not be used as a one-line dismissal, but it should not be ignored either. For peptide users, it is access, quality-control, compounding, and safety-signal context.

The FDA’s compounding-risk page, current as of April 22, 2026, lists GHRP-2, GHRP-6, ibutamoren mesylate, and ipamorelin acetate with specific potential safety risks for compounding contexts. CJC-1295 appears in the withdrawn-nomination table with concerns around impurities and reported serious adverse events. That does not mean "these compounds do nothing." It means non-branded, compounded, or research-market sourcing carries real quality and safety uncertainty.

FDA-approved drug exists; approval supports the evidence floor but does not guarantee grey-market vial quality

Prior FDA approval history; commonly treated as the most defensible compounding option

FDA 503B category-2 / withdrawn-nomination complexity; quality and route-safety concerns matter

CJC-1295

Withdrawn-nomination context; no-DAC version has no independent clinical program

Not a peptide; research-chemical / anti-doping / supplement-adulteration concerns

Older GHRPs with FDA compounding-risk context and WADA prohibition

All GH secretagogues are prohibited in tested sport. Under WADA and similar anti-doping rules the whole class is banned and detectable.

Frequently Asked Questions

How do GH peptides differ in complexity and evidence for initial use?

Ipamorelin is usually the entry point when the goal is a lower-noise GH pulse for sleep-window recovery, training recovery, or lean-mass support, dosed fasted at bedtime. Tesamorelin is not a beginner upgrade; it fits deep abdominal fat, GLP-1 lean-mass support, or a stronger GHRH-side signal as the actual target.

What evidence supports combining CJC-1295 and ipamorelin?

It is a reasonable architecture but a low-direct-evidence protocol. The general GHRH plus ghrelin-receptor synergy principle is real. The exact CJC no-DAC + ipamorelin pairing has no direct human trial, and CJC no-DAC itself has no published human trial. For a more conservative GHRH-side pairing, sermorelin + ipamorelin is easier to explain.

How do tesamorelin and ipamorelin differ?

Neither is universally better. Tesamorelin fits visceral-fat and recomp contexts. Ipamorelin fits short GH-pulse support with lower appetite and stress-hormone noise. They work through different receptor sides and can be paired in advanced protocols, but human data support tesamorelin alone, not the combination.

How do sermorelin and CJC-1295 differ?

Sermorelin is more conservative and has a clearer regulatory history. CJC no-DAC is popular because it is marketed as a stronger or more durable Modified GRF option, but it has no direct human trials. CJC DAC is a different weekly long-acting compound and should not be collapsed into the no-DAC protocol.

What current roles remain for GHRP-2 and GHRP-6?

Sometimes, but they should not be the modern default. GHRP-2 has historical value and can drive a strong GH pulse, but cortisol and prolactin can move with it. GHRP-6 is most relevant when appetite stimulation is deliberately wanted. For clean body-composition, sleep-window recovery, or GH-pulse support, ipamorelin usually replaces both.

What evidence supports GH-axis peptides during GLP-1-associated weight loss?

They can be useful when the issue is lean-mass preservation, tissue quality, or training recovery during a GLP-1 cut. Tesamorelin is the more relevant GH-axis compound for GLP-1 lean-mass support and visceral-fat phenotype. Ipamorelin can support a bedtime GH pulse, but it is not a substitute for protein, resistance training, or adequate calories.

How long until results appear?

Sleep and recovery changes can appear in 1-2 weeks if the axis is responsive. IGF-1 becomes more interpretable by weeks 4-8. Body-composition changes require months and depend heavily on training, protein, sleep, and glucose status. When sleep, recovery, and IGF-1 all stay flat past week 6-8, product quality, timing, food window, and pituitary reserve are what separate a non-responder from a non-response.

How does oral MK-677 compare with injectable GH-axis peptides in safety?

No. Oral dosing is easier, not safer. MK-677 can increase appetite, edema, fasting glucose, and cortisol. It also had a congestive-heart-failure signal in a frail post-fracture trial. It is a poor fit for glucose-vulnerable, edema-prone, or cardiovascularly fragile users.

References

¹ Sermorelin for adult GH insufficiency — Walker RF. "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" Clinical Interventions in Aging. 2006;1(4):307-308. PubMed 18046908

² Sermorelin pediatric approval and use review — Keating GM, Wellington K. "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency." BioDrugs. 2004;18(5):339-354. PubMed 18031173

³ GHRP pituitary activity discovery — Bowers CY et al. "On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone." Journal of Clinical Endocrinology & Metabolism. 1990;70(4):975-982. PubMed 2108187

⁴ GHRH + GHRP synergy determinants — Veldhuis JD, Bowers CY. "Determinants of joint GH-releasing hormone and GH-releasing peptide synergy in man." American Journal of Physiology -- Endocrinology and Metabolism. 2009;296(5):E1085-E1092. PubMed 19240251

⁵ GH secretagogues in hypogonadal body composition — Sinha DK et al. "Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males." Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159. PMC7108996

⁶ Tesamorelin Phase III in HIV — Falutz J et al. "Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV." New England Journal of Medicine. 2007;357:2359-2370. DOI

⁷ EGRIFTA prescribing information — FDA Prescribing Information, EGRIFTA (tesamorelin). 2019. FDA Label

⁸ Adult GHRH analog caveat — Khorram O et al. studied [Nle27]GHRH(1-29)-NH2, a close GHRH analog rather than strict sermorelin, in older adults; useful for direction, not a clean sermorelin body-composition anchor. Journal of Clinical Endocrinology & Metabolism. 1997;82(5):1472-1479. PubMed 9141536

⁹ FDA compounding-risk context — FDA. "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." Content current as of April 22, 2026. FDA

¹⁰ Ipamorelin selectivity discovery — Raun K et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561. PubMed 9849822

¹¹ Ipamorelin Phase II postoperative ileus — Beck DE et al. "Safety and efficacy of ipamorelin for postoperative ileus." International Journal of Colorectal Disease. 2014. PubMed 25331030

¹² CJC-1295 prolonged GH stimulation — Teichman SL et al. "Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295." Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. PubMed 16352683

¹³ CJC-1295 pulsatile GH persistence — Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295." Journal of Clinical Endocrinology & Metabolism. 2006;91:4792-4797. PubMed 17018654

¹⁴ CJC-1295 trial discontinuation — ConjuChem Biotechnologies. CJC-1295 Phase II trial discontinuation. 2006.

¹⁵ MK-677 two-year RCT in older adults — Nass R et al. "Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized Trial." Annals of Internal Medicine. 2008;149(9):601-611. PMC2757071

¹⁶ Ghrelin vs hexarelin vs GHRH comparison — Arvat E et al. "Endocrine activities of ghrelin, a natural growth hormone secretagogue, in humans." Journal of Clinical Endocrinology & Metabolism. 1997;82:3734-3740. PubMed 9285939

¹⁷ GH secretagogue safety and efficacy review — Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues." Sexual Medicine Reviews. 2018;6(1):45-53. PMC5632578

¹⁸ GH secretagogue combo raises IGF-1 — Sigalos JT et al. "Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels." American Journal of Men’s Health. 2017;11(6):1752-1757. PMC5675260

¹⁹ Anamorelin Japan approval for cachexia — Wakabayashi H et al. "The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers." Journal of Cachexia, Sarcopenia and Muscle. 2021;12(1):14-16. PMC7890143

²⁰ GHRP comparison — Ghigo E, Arvat E, et al. "Comparison of growth hormone releasing peptides." Journal of Pediatric Endocrinology & Metabolism. 2000. PubMed 10997607

²¹ GHRP-6 potency characterization — Bowers CY. "GHRP-6: a potent growth hormone-releasing peptide." Growth Hormone & IGF Research. 1998. PubMed 9467534

²² MK-677 sleep and activity effects in elderly — Copinschi G, Leproult R, et al. "Effects of MK-677 on sleep and activity in healthy elderly subjects." Neuroendocrinology. 1997. PubMed 17293569

²³ Hexarelin as GH secretagogue — Ghigo E, Arvat E, et al. "Hexarelin: a new growth hormone secretagogue." Journal of Endocrinological Investigation. 1997. PubMed 9776547

²⁴ MK-677 oral GH secretagogue characterization — Chapman IM, Bach MA, et al. "MK-677: an orally active growth hormone secretagogue." Journal of Clinical Endocrinology & Metabolism. 1996. PubMed 9467546

Medical Disclaimer

The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.